Skip to main navigation Skip to search Skip to main content

The Rac1 Promoter as a Molecular Nexus for Antihypertensive Therapy Resistance and Enhanced Malaria Susceptibility

  • Selassie Louis Ameke
  • , Kwadwo Fosu
  • , Lucas Amenga-Etego
  • , Kwabena Amofa Nketia Sarpong
  • , Samuel Kojo Kwofie
  • University of Ghana
  • Ghana Health Service

Research output: Contribution to journal › Article › peer-review

Abstract

Background: In Sub-Saharan Africa, the escalating burden of hypertension converges with persistent malaria endemicity, creating a complex clinical challenge marked by increasing rates of resistance to first-line antihypertensive therapies, particularly angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin II receptor blockers (ARBs). The molecular mechanisms underpinning this therapeutic failure remain elusive. Rac1, a Rho GTPase regulating both cardiovascular function and erythrocyte biology, presents a compelling molecular link between these comorbidities, yet its regulatory architecture in this context is uncharacterized. Methods: We conducted a comprehensive in silico analysis of the human Rac1 promoter region (−2000 to +500 bp relative to the transcription start site) using biomaRt, BSgenome, and the JASPAR2022 database, anchored to the GRCh38/hg38 reference genome. African ancestry variants from resources such as gnomAD were considered to enhance population-specific relevance. Transcription factor binding sites were predicted using position weight matrices with an 80% relative score threshold to balance sensitivity and specificity. CpG island analysis was performed, including calculation of the observed/expected (o/e) ratio. Results: The 2501 bp Rac1 promoter is notably GC-rich (57.34%) and contains 164 CpG sites with an o/e ratio of 0.75, defining a canonical CpG island. Analysis revealed a complex regulatory landscape featuring binding motifs for the mineralocorticoid receptor (MR), suggesting a potential pathway for bypassing RAAS blockade and contributing to ACEI/ARB resistance. Binding sites for hypoxia-inducible factors, inflammatory mediators, and the erythroid-specific factor GATA-1 were also identified. Spatial analysis showed nonrandom clustering of these elements, suggesting integrated response capabilities. Conclusion: The regulatory architecture of the Rac1 promoter suggests a potential molecular basis for MR-mediated resistance to ACEI/ARB therapies while simultaneously providing a predictive link to enhanced malaria susceptibility through erythrocyte remodeling pathways. These findings offer a novel framework for understanding treatment-resistant hypertension in malaria-endemic regions and identify the Rac1 promoter as a candidate nexus for developing dual-disease therapeutic strategies tailored to high-burden populations.

Original languageEnglish
Article number8287621
JournalInternational Journal of Hypertension
Volume2026
Issue number1
DOIs
Publication statusPublished - 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CpG island
  • Rac1
  • Sub-Saharan Africa
  • erythrocyte
  • hypertension
  • in silico analysis
  • malaria
  • mineralocorticoid receptor
  • promoter
  • therapy resistance

Fingerprint

Dive into the research topics of 'The Rac1 Promoter as a Molecular Nexus for Antihypertensive Therapy Resistance and Enhanced Malaria Susceptibility'. Together they form a unique fingerprint.

Cite this